New Study Finds Psychedelic Treatments More Effective than Typical Antidepressant Medications
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces…
Year: 2020
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
– Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in…
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in…
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
– PEDFIC 1 meets both U.S. and EU primary and secondary endpoints with highly statistically…
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
–Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study,…
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
– Findings support upcoming launch of T-Detect™ COVID, first T-cell test for novel coronavirus– Data…
CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Phesgo offers faster and less invasive delivery of standard of care treatment with Perjeta and…
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a…
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
– Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic…
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
U.S. Food and Drug Administration (FDA) clearance of PMV Pharmaceutical’s investigational new drug application for…
GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:…
Aditxt Provides Business Update and Files Third Quarter 2020 10-Q
Mountain View, CA, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Aditx Therapeutics, Inc….
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS),…
RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Larimar Therapeutics to Participate in Upcoming Investor Conferences
BALA CYNWYD, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR),…
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020
– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing…
BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate…
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
Company Management and Principal Investigator of ReSPECT to Discuss Interim Data Webinar Scheduled for Thursday,…
AIM ImmunoTech Provides Third Quarter 2020 Business Update
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM), an…
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company…